Preclinical studies in myeloproliferative neoplasms (MPNs) have evaluated several histone deacetylase inhibitors (HDACs), including panobinostat, vorinostat, givinostat, and PCI34051 (HDAC8-specific) (Table 1). Here, HDAC8 is linked to myeloproliferative disorder.